TNF Pharmaceuticals, Inc. (TNFA)
After hours:
- Business Wire
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
BALTIMORE, October 02, 2024--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has secured a strategic equity investment, priced at a 20% premium to a 30-trading days volume weighted average price (VWAP), from Prevail Partners, LLC, a U.S. investment fund focused on life sciences companies. The Company has engaged global ful
- Business Wire
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
BALTIMORE, August 21, 2024--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it is preparing to advance its lead program, MYMD-1®, through fully funded mid-stage clinical trials. MYMD-1 is a small molecule shown to block excessive activity of TNF-alpha (TNF-α) in the blood to regulate the immuno-metabolic
